STOCK TITAN

VERU 10-K Filings

VERU NASDAQ

Here are the 10-K annual reports from Veru Inc. (VERU) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow VERU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VERU filings page.

Form 10-K
Rhea-AI Summary

Veru Inc. has transformed into a late clinical stage biopharmaceutical company after selling its FDA-approved FC2 Female Condom business on December 30, 2024, a strategic shift that had a major effect on operations and financial results. The company now focuses on two drug candidates: enobosarm for obesity patients receiving GLP-1 receptor agonists and sabizabulin for inflammation in atherosclerotic cardiovascular disease.

Enobosarm, an oral selective androgen receptor modulator, produced positive Phase 2b QUALITY trial results in older obese patients on semaglutide, delivering a 100% relative reduction in lean mass loss at the 3 mg dose (p<0.001) and shifting weight loss almost entirely to fat. Extension data showed that enobosarm monotherapy reduced weight and fat regain after semaglutide was stopped, while maintaining a favorable safety profile. Veru plans a Phase 2b PLATEAU study in about 200 patients with obesity starting GLP-1 therapy and is developing a modified-release oral formulation it expects to use in Phase 3.

Sabizabulin, a microtubule disruptor targeting inflammatory pathways, is being advanced for stable coronary artery disease following an FDA pre-IND meeting, with an initial Phase 2 study planned to lower high-sensitivity C-reactive protein. Veru highlights risks from its history of losses, current lack of commercial revenue, dependence on external funding and Nasdaq listing compliance, and notes a 1-for-10 reverse stock split effective August 8, 2025. The board oversees an enterprise-wide cybersecurity program, and the company reports no cybersecurity threats that have materially affected its business to date.